Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus.
Siderophores are multidentate iron(III) chelators used by bacteria for iron assimilation. Sideromycins, also called siderophore-antibiotic conjugates, are a unique subset of siderophores that enter bacterial cells via siderophore uptake pathways and deliver the toxic antibiotic in a "Trojan horse" fashion. Sideromycins represent a novel antibiotic delivery technology with untapped potential for developing sophisticated microbe-selective antibacterial agents that limit the emergence of bacterial resistance. The chemical synthesis of a series of mono-, bis-, and trihydroxamate sideromycins are described here along with their biological evaluation in antibacterial susceptibility assays. The linear hydroxamate siderophores used for the sideromycins in this study were derived from the ferrioxamine family and inspired by the naturally occurring salmycin sideromycins. The antibacterial agents used were a β-lactam carbacepholosporin, Lorabid, and a fluoroquinolone, ciprofloxacin, chosen for the different locations of their biological targets, the periplasm (extracellular) and the cytoplasm (intracellular). The linear hydroxamate-based sideromycins were selectively toxic toward Gram-positive bacteria, especially Staphylococcus aureus SG511 (MIC = 1.0 μM for the trihydroxamate-fluoroquinolone sideromycin). Siderophore-sideromycin competition assays demonstrated that only the fluoroquinolone sideromycins required membrane transport to reach their cytoplasmic biological target and that a trihydroxamate siderophore backbone was required for protein-mediated active transport of the sideromycins into S. aureus cells via siderophore uptake pathways. This work represents a comprehensive study of linear hydroxamate sideromycins and teaches how to build effective hydroxamate-based sideromycins as Gram-positive selective antibiotic agents.
Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA.
Timothy A
TA
Wencewicz
Timothy E
TE
Long
Ute
U
Möllmann
Marvin J
MJ
Miller
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D005296:Ferrous Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D006877:Hydroxamic Acids / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D017262:Siderophores / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D005296:Ferrous Compounds; D024841:Fluoroquinolones; D006877:Hydroxamic Acids; D010455:Peptides; D017262:Siderophores; C016738:sideromycins